Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 901–1,000 of 1,014
Heat therapy: possible benefits for cognitive function and the aging brain
Schulze, A. T. V., Deng, F., Morris, J. K., & Geiger, P. C. (2020) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00168.2020 · Cited by 29
Knowledge gaps in Alzheimer's disease immune biomarker research
Morgan, D., & Mielke, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12342 · Cited by 27
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 31
“Previously tested anti-Aβ mAbs, such as solanezumab and bapineuzumab, had high intrinsic affinities for Aβ peptides in general (both have KD values in the low nM range [80]); therefore, they suffered from extensive target distraction and proved to be ineffective at reducing brain amyloid or affecting clinical outcomes…”
BackgroundAbelein, A., & Johansson, J. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00040k · Cited by 28
Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
Esquer, A., Blanc, F., & Collongues, N. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00541-1 · Cited by 27
“…showed a significant difference in its cognitive primary objective, the safety trend was clearly towards ARIA-E in the APOE4 carrier populations, with a rate of ARIA-E of 15% in the carrier trial compared with 4.2% for the same dose and 9.4% at higher doses of APOE4 in the non-carrier trial [37].”
ResultInfluentialZhang, J., Liu, Z., Zhang, H., Yang, C., He, L., Li, X., Chen, K., & Zhang, Z. (2016) · Scientific Reports · doi:10.1038/srep28982 · Cited by 28
Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials
Siderowf, A. D., Aarsland, D., Mollenhauer, B., Goldman, J. G., & Ravina, B. M. (2018) · Movement Disorders · doi:10.1002/mds.27355 · Cited by 28
“This has been clearly shown in an AD trial for bapineuzumab, a monoclonal antibody targeting Ab, in which over 30% of the 1,331 subjects clinically diagnosed with AD did not reach the imaging threshold for amyloid deposition.(107) In PD mutations in the gene encoding glucocerebrocidase (GBA) have emerged as a TABLE 2.”
BackgroundHanfelt, J., Peng, L., Goldstein, F. C., & Lah, J. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.025 · Cited by 29
“Unfortunately, to date, none of these trials has achieved their primary outcome measures (Cummings et al., 2017; Doody et al., 2014; Salloway et al., 2014).”
Boutajangout, A., Lindberg, H., Awwad, A., Paul, A., Baitalmal, R., Almokyad, I. K., Höidén‐Guthenberg, I., Gunneriusson, E., Frejd, F. Y., Härd, T., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00064 · Cited by 26
Effects of Combined Aerobic Exercise and Cognitive Training on Verbal Fluency in Older Adults
Nocera, J. R., Mammino, K., Kommula, Y., Wharton, W., Crosson, B., & McGregor, K. (2020) · Gerontology and Geriatric Medicine · doi:10.1177/2333721419896884 · Cited by 28
“Approaches to mitigate these declines over the past 20 years have largely been focused (at least monetarily) on pharmacological interventions, which have not yielded proportional returns for subsequent improvement in cognitive capacity (Honig et al., 2018; Salloway et al., 2014).”
BackgroundAntibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
“It is estimated that ∼20% of patients in the Bapineuzumab trial had dementia, but not as a result of AD (Salloway et al., 2014).”
BackgroundVukmir, R. B. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52042 · Cited by 28
“24,25 This finding is consistent with a class effect found in other amyloid-modifying therapy.”
Liu, W., Sun, F.-X., Wan, M., Jiang, F., Xiangyu, B. O., Lin, L., Tang, H., & Xu, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00969 · Cited by 27
“However, Phase 3 clinical trials of bapineuzumab were halted after the completion of two trials because it did not improve clinical outcomes in patients with AD (Salloway et al., 2014).”
BackgroundHerline, K., Prelli, F., Mehta, P. D., MacMurray, C., Goñi, F., & Wısnıewskı, T. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0384-9 · Cited by 26
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 25
Tichko, P., Kim, J. C., Large, E. W., & Loui, P. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15059 · Cited by 31
“Given the limited success of and the side effects associated with pharmacological interventions (Karran et al., 2011; Salloway et al., 2014) and the invasive nature of novel antibody interventions (Sevigny et al., 2016), alternative and non-invasive forms of care and treatment for…”
BackgroundZhang, X., Lin, L., Li, H., Xia, W., Liu, Q., Zhou, X., Lin, D., & Fu, X. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.158 · Cited by 27
Therapeutic anti‐amyloid β antibodies cause neuronal disturbances
Adhikari, U. K., Khan, R. H., Mikhael, M., Balez, R., David, M. A., Mahns, D. A., Hardy, J., & Tayebi, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12833 · Cited by 28
Preventing Alzheimer's disease by means of natural selection
Demetrius, L., & Driver, J. A. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0919 · Cited by 25
“Clinical studies to evaluate the predictions of the amyloid hypothesis have consistently failed [14–18].”
BackgroundSnellman, A., Rokka, J., Lopez‐Picon, F. R., Eskola, O., Salmona, M., Forloni, G., Scheinin, M., Solin, O. H., Rinne, J. O., & Haaparanta‐Solin, M. (2014) · EJNMMI Research · doi:10.1186/s13550-014-0037-3 · Cited by 29
“Positron emission tomography (PET) with the Aβ imaging agent [(11)C] Pittsburgh compound B ([(11)C]PIB) first established this as a valuable biomarker approach for evaluating changes in Aβ deposition [2,3].”
MethodDrugs and drug delivery systems targeting amyloid-β in Alzheimer's disease
Robinson, M., Lee, B., & Leonenko, Z. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.3.332 · Cited by 22
“Coupled with a safety concern, where MRI imaging showed abnormalities associated with vasogenic edema, clinical trials were discontinued [55].”
BackgroundRole of autophagy in the pathogenesis of Alzheimer disease
Kızılarslanoğlu, M. C., & Ülger, Z. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1407-75 · Cited by 24
“Researches on therapeutic strategies for AD have mainly focused on anti-Aβ strategies, but most recently, studies examining the effect of monoclonal antibodies against Aβ protein such as solanezumab and bapineuzumab have resulted in disappointment due to high toxicity or ineffectiveness (1,2).”
BackgroundIs Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?
van Eimeren, T., Bischof, G. N., & Drzezga, A. E. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190082 · Cited by 25
“The disappointing results of antiamyloid therapy approaches in AD (4,5) and the onset of novel anti-tau therapeutic concepts (6,7) have increased interest in the in vivo detection of tau pathology, which has been limited to postmortem examinations so far.”
BackgroundOligomeric tau-targeted immunotherapy in Tg4510 mice
Schroeder, S. K., Joly‐Amado, A., Soliman, A. S., Sengupta, U., Kayed, R., Gordon, M. N., & Morgan, D. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0274-6 · Cited by 25
“One of the first approaches to reducing brain Aβ was the use of immunotherapy [5, 6] and this approach has advanced to phase 3 clinical testing [7, 8].”
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.08.016 · Cited by 25
RetractedThe Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases
Dupont, A.-C., Largeau, B., Guilloteau, D., Ribeiro, M. J., & Arlicot, N. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/7043578 · Cited by 30
Min, K. C., Dockendorf, M. F., Palcza, J. S., Tseng, J., Ma, L., Stone, J. A., Kleijn, H. J., Hodsman, P., Masuo, K., Tanen, M., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1258 · Cited by 26
Grasping at straws: the failure of solanezumab to modify mild Alzheimer’s disease
Doggrell, S. A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1543397 · Cited by 26
Elran‐Barak, R., Weinstein, G., Beeri, M. S., & Ravona‐Springer, R. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.12.011 · Cited by 27
A blood-based signature of cerebrospinal fluid Aβ1–42 status
Goudey, B., Fung, B. J., Schieber, C., Faux, N. G., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37149-7 · Cited by 25
Self-citationEpelbaum, S., Paquet, C., Hugon, J., Dumurgier, J., Wallon, D., Hannequin, D., Jonveaux, T., Besozzi, A., Pouponneau, S., Hommet, C., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029663 · Cited by 27
Wang, G., Kennedy, R., Goldberg, T. E., Fowler, M. E., Cutter, G., & Schneider, L. S. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228064 · Cited by 27
“MMSE score of 16 to 19), though the thresholds may vary [1, 2, 31].”
BackgroundHe, H., Liu, A., Zhang, W., Yang, H., Zhang, M., Xu, H. J., Liu, Y., Hong, B., Feng, Y., Yue, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210307 · Cited by 25
Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 46
Ahmad, S. S., Khan, S. M., Kamal, M. A., & Wasi, U. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666191011145941 · Cited by 26
Deep Brain Stimulation in Alzheimer’s Disease: Targeting the Nucleus Basalis of Meynert
Chen, Y., Shu, K., & Kang, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201141 · Cited by 25
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Park, K. W. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00848-3 · Cited by 26
“Bapineuzumab is a humanized murine antibody directed toward N-terminal residues 1–5 of the Aβ protein [24].”
Fyn Kinase in Alzheimer’s Disease: Unraveling Molecular Mechanisms and Therapeutic Implications
Meur, S., & Karati, D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04286-2 · Cited by 28
Martínez‐Márquez, A., Carriel, J. M., Ramírez‐Estrada, K., Cusido, R. M., Sellés‐Marchart, S., Palazón, J., Pedreño, M. A., & Bru‐Martínez, R. (2015) · Journal of Biological Methods · doi:10.14440/jbm.2015.51 · Cited by 23
Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives
Wang, J., Tan, L., & Yu, J.-T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150826 · Cited by 23
Hempel, P., Heinig, B., Jerosch, C., Decius, I., Karczewski, P., Kassner, U., Kunze, R., Steinhagen‐Thiessen, E., & Bimmler, M. (2016) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12415 · Cited by 24
Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET
Guo, T., Brendel, M., Grimmer, T., Rominger, A., & Yakushev, I. Y. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.176115 · Cited by 25
“Consequently, they are commonly treated as target regions in antiamy-loid drug trials ( 4,8 – 10 ).”
Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease
Nakamura, N., Ohyagi, Y., Imamura, T., Yanagihara, Y. T., Iinuma, K., Soejima, N., Murai, H., Yamasaki, R., & Kira, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160344 · Cited by 24
“However, recent clinical trials using anti36 A antibody therapies have been unsuccessful [6, 7] 37 or only slightly effective in treating mild AD [8], and 38 anti-p-tau antibody therapies are still under investi39 gation in mouse models of disease [4].”
BackgroundTherapeutic Strategies for Alzheimer’s Disease in the View of Diabetes Mellitus
Ohyagi, Y., Miyoshi, K., & Nakamura, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_11 · Cited by 23
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 29
Does Diet Have a Role in the Treatment of Alzheimer's Disease?
Thelen, M., & Brown‐Borg, H. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.617071 · Cited by 25
“In short, mTORC1 activation leads to protein translation and cell growth, whereas its inhibition blocks growth and induces stress response pathways, such as autophagy, leading to pro-longevity effects (Laplante and Sabatini, 2012; Saxton and Sabatini, 2017).”
BackgroundAsih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 25
Smith, G. S., Protas, H., Kuwabara, H., Savonenko, A., Nassery, N., Gould, N. F., Kraut, M., Avramopoulos, D., Holt, D., Dannals, R. F., et al. (2023) · NeuroImage: Clinical · doi:10.1016/j.nicl.2023.103322 · Cited by 22
“…January 2023 NeuroImage: Clinical 37 (2023) 103322 Further, in AD patients, clinical progression despite brain clearance of Aβ by immunization, further highlights the importance of understanding aspects of neurodegeneration associated with Aβ deposition (Holmes et al., 2008; Salloway et al., 2014).”
BackgroundMolecular Therapeutics in Development to Treat Alzheimer’s Disease
Tartaglia, M. C., & Ingelsson, M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00738-6 · Cited by 25
Zhao, Y., Zhao, W., Chai, X., Sun, P., Huang, J., Guo, X., Zhang, L., Ren, D., Yi, C., Zhu, X., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.04.025 · Cited by 34
DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells
Xiang, J., Zhang, W., Cai, X., Cai, M., Yu, Z., Yang, F., Zhu, W., Li, X.-T., Wu, T., Zhang, J., et al. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.02.025 · Cited by 19
Cell size effects in the molecular dynamics of the intrinsically disordered Aβ peptide
Mehra, R., & Kepp, K. P. (2019) · The Journal of Chemical Physics · doi:10.1063/1.5115085 · Cited by 24
Li, Y., Dai, S., Huang, N., Wu, J., Yu, C., & Luo, Y. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2114 · Cited by 26
Alves, I. L., Heeman, F., Collij, L. E., Salvadó, G., Tolboom, N., Vilor‐Tejedor, N., Markiewicz, P. J., Yaqub, M. M., Cash, D. M., Mormino, E. C., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00819-2 · Cited by 24
Preventing Alzheimer's disease within reach by 2025: Targeted‐risk‐AD‐prevention (TRAP) strategy
Vitali, F., Branigan, G. L., & Brinton, R. D. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12190 · Cited by 35
Morsy, A., Krishnaiah, M., Gao, J., Wang, H., Valdez, J., Dow, L. F., Wang, X., & Trippier, P. C. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00246 · Cited by 23
Collij, L. E., Farrar, G., García, D. V., Bader, I., Shekari, M., Lorenzini, L., Pemberton, H., Altomare, D., Pla, S., Loor, M., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1063598 · Cited by 24
“After some years of clinical use of the amyloid PET tracers, the appropriate use criteria (AUC) were drafted (5, 6) and today amyloid-PET imaging is more frequently used in a clinical setting.”
BackgroundMethodRecent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer’s Disease
Su, M., Nizamutdinov, D., Liu, H., & Huang, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119272 · Cited by 28
Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 25
Leung, K. K., Malone, I. B., Sebastien Ourselin, A., Gunter, J. L., Bernstein, M. A., Thompson, P. M., Jack, C. R., Weiner, M. W., & Fox, N. C. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.049 · Cited by 25
“Rates of brain atrophy measured from serial MRI are increasingly used to track disease progression for diagnostic purposes and clinical trials (Johnson et al., 2012; Salloway et al., 2014).”
Self-citationProtein structures in Alzheimer's disease: The basis for rationale therapeutic design
Montoliu‐Gaya, L., & Villegas, S. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.10.005 · Cited by 28
A Systems View of the Differences between APOE ε4 Carriers and Non-carriers in Alzheimer’s Disease
Jiang, S., Tang, L. Y., Zhao, N., Yang, W., Qiu, Y. L., & Chen, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00171 · Cited by 24
“A higher dose of bapineuzumab, an anti-β-amyloid peptide (Aβ) monoclonal antibody, is needed to decrease cerebrospinal fluid phospho-tau concentration in APOE ε4 non-carriers than in carriers (Salloway et al., 2014).”
BackgroundRecapitulating Amyloid ß and Tau Pathology in Human Neural Cell Culture Models—Clinical Implications
Choi, S. H., Kim, Y. H., D’Avanzo, C., Aronson, J., Tanzi, R. E., Kim, D. Y., Associate, P., & Professor (2015) · touchREVIEWS in Neurology · doi:10.17925/usn.2015.11.02.102 · Cited by 29
Blockx, I., Einstein, S., Guns, P.-J., Van Audekerke, J., Guglielmetti, C., Zago, W., Roose, D., Verhoye, M., Van der Linden, A., & Bard, F. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160023 · Cited by 21
Liu, Y., Jiang, L., & Li, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6006 · Cited by 23
“However, the results of phase III trials involving anti-amyloid treatment of AD with solanezumab and bapineuzumab have yielded disappointing results (5,6).”
Finke, J. M., & Banks, W. A. (2016) · Human Antibodies · doi:10.3233/hab-160306 · Cited by 24
“The treatments did shift A β and/or tau biomarkers in the desired direction [54,126] and select patient subgroups showed a possible bene-fit [54,86].”
InfluentialAntibody blood-brain barrier efflux is modulated by glycan modification
Finke, J. M., Ayres, K. R., Brisbin, R. P., Hill, H. A., Wing, E. E., & Banks, W. A. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.06.008 · Cited by 21
Biomarkers: Delivering on the expectation of molecularly driven, quantitative health
Wilson, J. L., & Altman, R. B. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217744775 · Cited by 27
Cheng, Q., Hu, Z., Doherty, K. E., Tobin-Miyaji, Y. J., & Qiang, W. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.008 · Cited by 25
“However, it is worth noting that some of these drugs, such as Bapineuzumab and Semagacestat, did reduce the production of Aβ or clear the existing Aβ plaques in early-phase clinic tests [3,5].”
BackgroundLinks Between Adiponectin and Dementia: From Risk Factors to Pathophysiology
Chen, R., Shu, Y., & Zeng, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00356 · Cited by 26
Mondal, S., Vashi, Y., Ghosh, P., Roy, D., Barthakur, M., Kumar, S., & Iyer, P. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00387 · Cited by 22
Ugbaja, S. C., Lawal, I. A., Kumalo, H. M., & Lawal, M. M. (2021) · Current Drug Targets · doi:10.2174/1389450122666210809100050 · Cited by 22
Hao, L., Jia, J., Xing, Y., & Han, Y. (2021) · Aging & Mental Health · doi:10.1080/13607863.2021.1980860 · Cited by 24
Prion-like strain effects in tauopathies
Han, Z. Z., Kang, S., Arce, L., & Westaway, D. A. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03620-1 · Cited by 25
Mehrazma, B., Robinson, M. J., Opare, S. K. A., Petoyan, A., Lou, J. W., Hane, F. T., Rauk, A., & Leonenko, Z. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.07.022 · Cited by 23
“The common classes of drugs being explored that target Aβ are small nonspecific molecules (e.g., tramiprosate and flurizan) [14,15], or very large specific monoclonal antibodies (MAbs) including Bapineuzumab and Solanezumab [16,17]; to date these interventions have failed in or before Phase III clinical trials [16–20].”
BackgroundAlzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Both trials failed to show a treatment effect on cognitive or functional primary outcomes or rate of brain volume loss (61).”
BackgroundOjo, J. O., Reed, J. M., Crynen, G. C., Vallabhaneni, P., Evans, J., Shackleton, B., Eisenbaum, M., Ringland, C., Edsell, A., MULLAN, M. J., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.658605 · Cited by 23
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
“Bapineuzu-mab, the fi rst tested antibody in clinical trials, showed that although it tended to improve cognitive function, the results were not statistically signi fi cant [16].”
Zhang, H., Chen, Y., Yu, M., Xi, Y., Han, G., Jin, Y., Wang, G.-J., Sun, X., Zhou, J., & Ding, Y. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304213120 · Cited by 21
“Although clinical trials of solanezumab and ponezumab were designed for blood A β clearance, these agents can only induce A β efflux from the brain through a vacuum sucking effect (36, 37).”
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Mukherjee, A., Biswas, S., & Roy, I. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103974 · Cited by 23
Topical cyclodextrin reduces amyloid beta and inflammation improving retinal function in ageing mice
Kam, J. H., Lynch, A., Begum, R., Cunea, A., & Jeffery, G. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.023 · Cited by 21
Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease
Guo, S., Getsios, D., Revankar, N., Xu, P., Thompson, G., Bobula, J. D., Lacey, L. A., & Gaudig, M. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0203-5 · Cited by 22
Role of Hybrid Brain Imaging in Neuropsychiatric Disorders
Burhan, A. M., Marlatt, N. E., Palaniyappan, L. K., Anazodo, U., & Prato, F. S. (2015) · Diagnostics · doi:10.3390/diagnostics5040577 · Cited by 25
“susceptibility gene marker for the risk to develop AD) [61].”
BackgroundPostupna, N. O., Keene, C. D., Crane, P. K., Gonzalez‐Cuyar, L. F., Sonnen, J. A., Hewitt, J. L., Rice, S., Howard, K., Montine, K. S., Larson, E. B., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000153 · Cited by 23
“Cerebral cortical AA42 levels were consistently greater in those with an APOE D4 allele compared with those without in both diagnostic groups and in all regions, consistent with results from positron emission tomography (PET) studies with amyloid binding agents (2, 24).”
BackgroundResultIatrou, A., Kenis, G., Rutten, B. P. F., Lunnon, K., & van den Hove, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2361-4 · Cited by 25
Wang, Z., Xiong, L., Wan, W., Duan, L., Bai, X., & Zu, H. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00032 · Cited by 22
Burdensome Research Procedures in Trials: Why Less Is More
Kimmelman, J., Resnik, D. B., Peppercorn, J. M., & Ratain, M. J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw315 · Cited by 21
Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease
Gamage, K. K., & Kumar, S. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0420-17.2017 · Cited by 22
An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer’s disease
Marcelli, S., Ficulle, E., Piccolo, L., Corbo, M., & Feligioni, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.023 · Cited by 23
Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease?
Willbold, D., & Kutzsche, J. (2019) · Molecules · doi:10.3390/molecules24122237 · Cited by 21
Güell‐Bosch, J., Lope‐Piedrafita, S., Esquerda‐Canals, G., Montoliu‐Gaya, L., & Villegas, S. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4263 · Cited by 21
“This scFv, which is directed to the Aβ1–5 peptide, was designed by our group(28,29) based on the bapineuzumab monoclonal antibody (mAb), whose development was finally stopped in phase III clinical assays.(30) Several mAbs failed to show efficacy in protecting from mental decline in clinical trials,(30,31) including th…”
MethodArastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21
“PET scanning showed significant target engagement in two phase 3 Aβ immunotherapy clinical trials; no clinical improvement was evident [22].”
BackgroundWang, S., Leem, J. S., Podvin, S., HOOK, V. Y. H., Kleschevnikov, N., Savchenko, P., Dhanani, M., Zhou, K., Kelly, I., Zhang, T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.021 · Cited by 24
Samtani, M. N., Xu, S. X., Russu, A., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S. V., Brashear, H. R., Styren, S. D., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.09.001 · Cited by 21
“Detailed baseline patient characteristics of the two studies are published [12].”
BackgroundMethodInfluentialSelf-citationMicroglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease
Xie, J., Wang, H., Lin, T., & Bi, B. (2017) · BioMed Research International · doi:10.1155/2017/2986460 · Cited by 22
Salloway, S., Sperling, R. A., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H. Z., Ketter, N., Wang, D., Liu, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171157 · Cited by 23
“Infusion of bapineuzumab 0.5 or 1.0 mg/kg every 13 weeks was generally well tolerated, with a safety profile that was similar to the parent studies [3].”
InfluentialSelf-citationFailure After Failure. What Next in AD Drug Development?
Aisen, P. S. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.23 · Cited by 23
Ventura‐Antunes, L., Nackenoff, A. G., Romero‐Fernandez, W., Wang, Y., Bosworth, A. M., Prusky, A., Wang, E., Carvajal‐Tapia, C., Shostak, A., Harmsen, H. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70254 · Cited by 27
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.